|

Immunotherapy Clinical Trials

29 actively recruiting trials across 3 locations

▼ -2 trials since June 2026

Also known as: ICI, Immune checkpoint inhibitor, Immunological, Immunological Therapy, Immunologically Directed Therapy +6 more

Pipeline

Phase 1: 1Phase 2: 12Phase 3: 4Phase 2/3: 2

Top Sponsors

  • Shanghai Chest Hospital2
  • Fudan University2
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences2
  • Zhejiang Cancer Hospital1
  • University of Washington1

Indications

Other26 trials

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.
Phase 3
AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer
Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC
Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer
N/A
Association of Psychological Distress in Patients With Lung Cancer
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases
Phase 2
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Phase 3
Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC
Phase 2
Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer
Phase 2
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
Phase 2
DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
Phase 2
Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers
N/A
Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer
Phase 2/3
Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer
Phase 2
Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma
Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC
Phase 2
Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management
Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC
Phase 2
Neoadjuvant Treatment Modalities in Esophageal Cancer
Phase 3
PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
Phase 2
Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
Phase 2
Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)
Phase 2
TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
Phase 3
The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China
Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma
Phase 2/3
Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
Phase 2

San Diego, California1 trial

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Investigative Site #101

Phase 1

Columbia, Missouri1 trial

Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

University of Missouri - Ellis Fischel Cancer Center

Seattle, Washington1 trial

PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer

Fred Hutch/University of Washington Cancer Consortium

N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.